Cover Image

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic myeloid leukemia (CML). Although experience is too limited to permit evidence-based evaluation of survival, the available data fully justify critical reassessment of CML management. The panel therefore reviewed tr...

Full description

Saved in:
Bibliographic Details
Main Authors: Baccarani, Michele (Author) , Saglio, Giuseppe (Author) , Goldman, John (Author) , Hochhaus, Andreas (Author) , Simonsson, Bengt (Author) , Appelbaum, Frederick (Author) , Apperley, Jane (Author) , Cervantes, Francisco (Author) , Cortes, Jorge (Author) , Deininger, Michael (Author) , Gratwohl, Alois (Author) , Guilhot, François (Author) , Horowitz, Mary (Author) , Hughes, Timothy (Author) , Kantarjian, Hagop (Author) , Larson, Richard (Author) , Niederwieser, Dietger (Author) , Silver, Richard (Author) , Hehlmann, Rüdiger (Author)
Format: Article (Journal)
Language:English
Published: September 15, 2006
In: Blood
Year: 2006, Volume: 108, Issue: 6, Pages: 1809-1820
ISSN:1528-0020
DOI:10.1182/blood-2006-02-005686
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood-2006-02-005686
Get full text
Author Notes:Michele Baccarani, Giuseppe Saglio, John Goldman, Andreas Hochhaus, Bengt Simonsson, Frederick Appelbaum, Jane Apperley, Francisco Cervantes, Jorge Cortes, Michael Deininger, Alois Gratwohl, François Guilhot, Mary Horowitz, Timothy Hughes, Hagop Kantarjian, Richard Larson, Dietger Niederwieser, Richard Silver, and Rudiger Hehlmann
Description
Summary:The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic myeloid leukemia (CML). Although experience is too limited to permit evidence-based evaluation of survival, the available data fully justify critical reassessment of CML management. The panel therefore reviewed treatment of CML since 1998. It confirmed the value of IM (400 mg/day) and of conventional allogeneic hematopoietic stem cell transplantation (alloHSCT). It recommended that the preferred initial treatment for most patients newly diagnosed in chronic phase should now be 400 mg IM daily. A dose increase of IM, alloHSCT, or investigational treatments were recommended in case of failure, and could be considered in case of suboptimal response. Failure was defined at 3 months (no hematologic response [HR]), 6 months (incomplete HR or no cytogenetic response [CgR]), 12 months (less than partial CgR [Philadelphia chromosome-positive (Ph+) > 35%]), 18 months (less than complete CgR), and in case of HR or CgR loss, or appearance of highly IM-resistant BCR-ABL mutations. Suboptimal response was defined at 3 months (incomplete HR), 6 months (less than partial CgR), 12 months (less than complete CgR), 18 months (less than major molecular response [MMolR]), and, in case of MMolR loss, other mutations or other chromosomal abnormalities. The importance of regular monitoring at experienced centers was highlighted.
Item Description:Gesehen am 11.05.2022
Physical Description:Online Resource
ISSN:1528-0020
DOI:10.1182/blood-2006-02-005686

Similar Items